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Abstract
 
B lymphocyte stimulator (BLyS) is a novel member of the TNF ligand superfamily that is
important in B cell maturation and survival. We demonstrate that human neutrophils, after
incubation with G-CSF or, less efficiently, IFN
 
 
 
, express high levels of BLyS mRNA and
release elevated amounts of biologically active BLyS. In contrast, surface expression of the
membrane-bound BLyS was not detected in activated neutrophils. Indeed, in neutrophils,
uniquely among other myeloid cells, soluble BLyS is processed intracellularly by a furin-type
convertase. Worthy of note, the absolute capacity of G-CSF–stimulated neutrophils to release
BLyS was similar to that of activated monocytes or dendritic cells, suggesting that neutrophils
might represent an important source of BLyS. In this regard, we show that BLyS serum levels
as well as neutrophil-associated BLyS are significantly enhanced after in vivo administration of
G-CSF in patients. In addition, serum obtained from two of these patients induced a remarkable
accumulation of neutrophil-associated BLyS in vitro. This effect was neutralized by anti–G-CSF
antibodies, indicating that G-CSF, present in the serum, stimulated neutrophils to produce BLyS.
Collectively, our findings suggest that neutrophils, through the production of BLyS, might play
an unsuspected role in the regulation of B cell homeostasis.
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Introduction
 
The B lymphocyte stimulator (BLyS;
 
*
 
 also known as B cell
activator factor belonging to the TNF family [BAFF], TNF
homologue that activates apoptosis, NF-
 
 
 
B, and JNK
[THANK], TNF- and ApoL-related leukocyte-expressed
ligand 1 [TALL-1], and zTNF4), is a recently identified novel
member of the TNF ligand superfamily that is important in
B cell differentiation, survival, and regulation of immuno-
globulin production (1–3). Its requirement for the humoral
immune response is evident in mice lacking BLyS,
which exhibit profound deficiencies in peripheral B cell
development and maturation (2, 3). In addition, mice
transgenic for BLyS develop autoimmune disorders such
as increased germinal center formation, production of
autoantibodies, and Ig deposition in kidneys (2, 3).
BLyS exists as a type II membrane protein as well as a
soluble protein derived from the membrane-bound form
by cleavage with a putative furin family protease (4, 5). The
expression of BLyS protein seems to be mainly, but not
exclusively, restricted to cells of myeloid origin, as demon-
strated by studies showing the capacity of monocytes,
macrophages, monocyte-derived dendritic cells (mono-
DC), and leukemia myeloid cell lines (HL-60, U937, and
THP-1) to produce both the membrane-bound and the
soluble forms (5). However, whether mature neutrophils,
which are known to express a variety of ligands of the TNF
family (6), also produce BLyS has never been investigated.
The aim of this paper is to analyze whether neutrophils
synthesize and release BLyS, and to investigate how a
possible BLyS production by these cells could be regulated.
 
Materials and Methods
 
Cell Culture and Analysis.
 
Highly purified granulocytes
 
(neutrophils 
 
 
 
 96.5%; eosinophils 
 
 
 
 3%), PBMC, monocytes,
 
Address correspondence to Marco A. Cassatella, Dept. of Pathology,
General Pathology Unit, Strada Le Grazie 4, 37134 Verona, Italy. Phone:
39-045-8027130; Fax: 39-045-8027127; E-mail: marco.cassatella@univr.it
 
*
 
Abbreviations used in this paper:
 
 BLyS, B lymphocyte stimulator; HD,
Hodgkin’s; mono-DC, monocyte-derived dendritic cells. T
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and monocyte-derived dendritic cells (mono-DC) were isolated
under endotoxin-free conditions as described previously (5, 7).
Immediately after purification, cells were suspended in RPMI
1640 medium supplemented with 10% heat-inactivated FBS
(
 
 
 
0.009 ng/ml; Seromed Biochrom KG), usually treated with
1,000 U/ml G-CSF (lenograstim; Chugai Pharmaceutical Co.,
Ltd.) or 200 U/ml IFN
 
 
 
 (Hoffmann-La Roche) and subse-
quently incubated at 37
 
 
 
C, 5% CO
 
2
 
 atmosphere. In selected
experiments, G-CSF– or IFN
 
 
 
-stimulated neutrophils were
cultured in the presence or absence of the furin convertase in-
hibitor decanoyl-Arg-Val-Lys-Arg-chloromethylketone (CMK;
Qbiogene).
 
ELISA.
 
BLyS-specific ELISA was conducted as described
previously (5). IL-1ra and G-CSF were measured by using
ELISA commercial kits from Biosource International and
R&D Systems, respectively.
 
RNA Isolation and Northern Blot Analysis.
 
Total RNA from
neutrophils and PBMC was extracted and analyzed by Northern
blot for BLyS, IL-1ra, CXCL-11, and actin mRNA expression,
as described previously (7).
 
Staining of Membrane-bound and Intracellular BLyS.
 
Surface ex-
pression of membrane-bound BLyS was analyzed by flow cytom-
etry analysis using biotinylated anti-BLyS mAbs (3D4) or bio-
tinylated isotype anti–mouse IgG
 
1 
 
as described previously (5, 7).
 
Immunocytochemistry.
 
Staining of intracellular BLyS was per-
formed using goat anti-BLyS polyclonal Abs and negative control
Abs (R&D) according to Grenier et al. (8).
 
Western Blot Analysis.
 
For the direct immunodetection of
BLyS forms, whole-cell lysates from neutrophils were prepared as
described previously (7), and then analyzed using a rabbit anti-
BLyS polyclonal Abs (Cat. No. 07–167; Upstate Biotechnology).
Lysates prepared from HL-60 cells, as well as rBLyS, were also
run as positive controls for membrane-bound BlyS and soluble
BLyS, respectively.
 
Proliferation and Survival of B Cells.
 
Culture media, condi-
tioned either by neutrophils stimulated with 100 U/ml G-CSF or
by G-CSF only, were concentrated (9) and used in a proliferation
assay of human tonsillar B cells, as well as in a survival assay of
murine splenocytes, exactly as described previously (5, 10).
 
Patients.
 
10 patients affected by different hematological non-
myeloid malignancies (six multiple myeloma, two Hodgkin’s
[HD], and one non-HD lymphoma), undergoing high dose
chemotherapy (CT) and autologous peripheral stem cell trans-
plantation (APSCT) at the Hematology Unit of the University
of Verona, were enrolled for this work. G-CSF (lenograstim)
was administered as a daily subcutaneous dose of 300 
 
 
 
g from
day 2 to day 14 after transplant. BLyS was measured in serum
and leukocyte samples collected before conditioning CT (T-0)
and from day 12 to day 14 after transplant (T-G-CSF), when
neutrophil count resulted 
 
 
 
1,000/
 
 
 
l. Three patients (two HD
lymphoma and one non-HD lymphoma) who were submitted
to standard dose CT and APSCT without receiving G-CSF
support served as controls. In selected experiments, T-0 and
T-G-CSF serum samples from two different patients were pre-
incubated (at a final 20% vol/vol concentration) for 2 h at 37
 
 
 
C
with or without 5 
 
 
 
g/ml neutralizing anti–G-CSF polyclonal
Abs (R&D Systems) or negative control Abs, and then added to
neutrophils isolated from normal donors. After 21 h of culture,
neutrophils were lysed and antigenic BLyS was measured in
cell-associated pellets.
 
Statistical Analysis.
 
Data are expressed as means 
 
 
 
 SEM. Sta-
tistical evaluation was performed by the Student’s 
 
t
 
 test for paired
data and considered significant if P 
 
  
 
0.05.
 
Results and Discussion
 
BLyS Production by Activated Neutrophils.
 
Having ob-
served that G-CSF– or IFN
 
 
 
-treated neutrophils express
high levels of BLyS mRNA (Fig. 1, A and B), and having
excluded that this response might reflect contamination by
PBMC (Fig. 1 B), we next investigated whether neutro-
phils can also produce the BLyS protein. Fig. 1 C shows
that untreated cells constitutively release small but detect-
Figure 1. BLyS mRNA expression and release by activated neutro-
phils. (A) Purified populations of neutrophils were incubated with 1,000
U/ml G-CSF. At the time points indicated, total RNA was extracted and
analyzed for BLyS, IL-1ra, and actin mRNA expression by Northern
blotting. (B) Neutrophils and PBMC purified from the same donor were
cultured for 21 h with or without 200 U/ml IFN , and then were
subjected to Northern blot analysis for BLyS, CXCL-11/I-TAC, and
actin mRNA expression. Data are representative of results from at
least two independent experiments for each panel. (C) Neutrophils were
incubated for up to 42 h at 37 C with 1,000 U/ml G-CSF and 200 U/ml
IFN . Culture supernatants were harvested and processed for BLyS
detection by a specific ELISA. Values represent means   SEM of duplicate
determinations calculated from four independent experiments. The
asterisks represent significant differences between stimulated and resting
neutrophils. **, P   0.01. (D) PBMC, monocytes, and mono-DC were
cultured in the presence or the absence of 200 U/ml IFN  for 3 d.
Culture supernatants were collected, and the levels of BLyS were measured
by ELISA. Values represent the means of duplicate determinations calculated
from two independent experiments.T
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able amounts of BLyS, whereas significant quantities of
BLyS were secreted in response to either G-CSF or IFN
 
 
 
and progressively accumulated into the supernatants up to
42 h. Estimation of neutrophil apoptosis by propidium io-
dide staining and flow cytometric analysis substantiated the
notion that G-CSF and IFN
 
 
 
 possess a strong capacity to
significantly maintain neutrophil survival (9). Dose–
response experiments confirmed that 1,000 U/ml of
G-CSF and 200 U/ml of IFN
 
 
 
 represented optimal stimu-
latory concentrations for BLyS release (unpublished data).
In contrast, other mediators such as IL-4, TGF
 
 
 
, IL-10,
IL-13, TNF
 
 
 
, GM-CSF, and fMLP, used at optimal stim-
ulatory concentrations, failed to increase the basal release of
BLyS. Secretion of BLyS by neutrophils, and not by con-
taminating cells, was substantiated by the findings that
PBMC, on a per cell basis, secreted equivalent amounts of
BLyS in response to IFN
 
 
 
 (Fig. 1 D), and that G-CSF–
stimulated eosinophils were completely unable to release
BLyS (unpublished data). Importantly, experiments using
stimulated monocytes and mono-DC from additional do-
nors showed yields of BLyS similar to those detected in the
supernatants from G-CSF–stimulated neutrophils (Fig. 1 D).
Subsequently, we measured total BLyS production in ac-
tivated neutrophils, i.e., released BLyS in parallel with cell-
associated BLyS. These experiments demonstrated that
treatment of neutrophils for 21 h with either G-CSF or,
less efficiently, IFN
 
  
 
induced a dramatic increase of total
BLyS synthesis relative to cells treated with medium only
(Fig. 2 A). Time course studies revealed that total BLyS
synthesis started 6 h after cytokine treatment and linearly
increased up to 42 h (unpublished data). Interestingly, the
percentage of secreted BLyS relative to the total was higher
in neutrophils stimulated with both G-CSF and IFN
 
 
 
(45 
 
 
 
 12 and 51 
 
 
 
 10%, respectively) than in untreated cells
(30 
 
 
 
 2%; Fig. 2 A), suggesting that G-CSF and IFN
 
 
 
 en-
hance not only the synthesis, but also the rate of secretion
of BLyS. Because our ELISA did not permit us to discrimi-
nate between the membrane-bound and the secreted BLyS
forms, G-CSF–treated neutrophils were analyzed by flow
cytometry and immunocytochemistry. G-CSF was chosen
as the stimulus to be used in this and all subsequent assays,
not only because of its highest capacity to trigger BLyS
production and secretion, but also because of its specificity
as a neutrophil agonist. As reported in Fig. 2 B, both
IFN
 
 
 
- (not depicted) and G-CSF–treated neutrophils were
negative in FACS
 
®
 
 analysis for surface BLyS expression,
whereas membrane-bound BLyS was readily detectable on
HL-60 (Fig. 2 C). However, immunocytochemical analysis
(Fig. 2 D), as well as intracellular staining of permeabilized
neutrophils (unpublished data) confirmed that G-CSF (but
not GM-CSF) induced a specific increase of intracellular
BLyS (unpublished data), supporting the ELISA findings on
a BLyS de novo synthesis in G-CSF–treated neutrophils
(Fig. 2 A)
 
.
 
 In the experiments performed for the detection
of membrane-bound BLyS, neutrophils and HL-60 cells
were also cultured in the presence of CMK, a specific furin
convertase inhibitor. The treatment dramatically increased
surface-bound BLyS in HL-60 (Fig. 2 C), which is consis-
 
tent with the fact that, in these cells, cleavage of mem-
brane-bound BLyS by furin convertase is required for
BLyS production (4, 5). In contrast, membrane-bound
BLyS did not appear on neutrophils cultured in the pres-
ence of the inhibitor (Fig. 2 B).
 
BLyS Processing Takes Place at the Intracellular Level.
 
To
unequivocally identify the intracellular BLyS specie(s)
present in neutrophils, we performed immunoblots of
whole-cell extracts, using anti-BLyS Abs recognizing the
Figure 2. Lack of membrane-bound BLyS expression in neutrophils.
(A) Neutrophils (5   106/ml) were incubated for 21 h at 37 C with
1,000 U/ml G-CSF and 200 U/ml IFN . Cell-free supernatants and the
corresponding pellets were harvested and antigenic BLyS determined in
each compartment. The mean values   SEM of the total production of
BLyS (depicted as cell-associated and released) from four independent
experiment are shown. Asterisks represent significant differences between
stimulated and resting neutrophils. *, P   0.05; ***, P   0.001. (B and C)
Neutrophils were cultured for 21 h with 1,000 U/ml G-CSF, in the
absence or presence of 25  M CMK. HL-60 cells were cultured for 21 h
in the absence or presence of 50  M CMK. Membrane-bound BLyS
expression was examined by FACS® analysis using biotinylated 3D4
mAbs followed by PE-conjugated streptavidin. (D) Immunocytochemical
staining of intracellular BLyS performed in cytospin preparations of neutro-
phils incubated for 21 h with 1,000 U/ml G-CSF. Data are representative
of results from at least two independent experiments for each panel.T
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nonprocessed 32-kD protein, as well as the cleaved 17-kD
form (reference 4; Fig. 3 A, arrows). These experiments con-
firmed that HL-60 cells (Fig. 3 A), THP-1 cells, monocytes,
and mono-DC (not depicted) constitutively synthesize the
32-kD BLyS protein (corresponding to the membrane-
bound BLyS), which is consistent with the notion that re-
lease of BLyS by these cell types results by proteolytic cleav-
age of the membrane-bound protein (5). In contrast, lysates
from unstimulated neutrophils contained the 32- and 17-kD
(corresponding to rBLyS) proteins (4, 5), which both dra-
matically increased on cell treatment with G-CSF (Fig. 3 A).
Treatment with CMK completely inhibited the expression
of the 17-kD protein, but not of the 32-kD one (Fig. 3 A).
Accordingly, CMK suppressed the release of BLyS by
G-CSF–treated neutrophils (Fig. 3 B). The inhibition was
neither caused by drug toxicity—because IL-1ra production
was unaffected (Fig. 3 B)—nor exerted at the transcriptional
level—because G-CSF–induced BLyS mRNA accumula-
 
tion was not influenced by CMK (not depicted). Together,
our data indicate that in neutrophils, BLyS is released after
intracellular processing of the longer form by a furin conver-
tase–like enzyme. In this context, APRIL/TRDL-1
 
 
 
, an-
other recently identified TNF family member closely related
to BLyS, was shown to be processed in a similar manner
(11). The fact that neutrophils, but not PBMC or DC, pro-
cess BLyS intracellularly indicates that the mechanisms regu-
lating BLyS expression are cell-type characteristic and are
subjected to distinct regulatory pathways.
 
Biological Activities of Neutrophil-derived Supernatants.
 
To
ascertain whether BLyS released by neutrophils was biologi-
cally active, we initially tested the ability of neutrophil-
derived supernatants in a standard B cell costimulation assay.
As shown in Fig. 4 A, BLyS contained in conditioned medium
obtained from G-CSF–stimulated neutrophils (used at the fi-
nal concentration of 5 ng/ml) induced an approximately
twofold increase of B cell [
 
3
 
H]thymidine uptake, whereas
Figure 3. BLyS processing takes
place at the intracellular level. (A)
1 ng/lane rBLyS and whole-cell
extracts prepared from 40  g un-
stimulated HL-60 cells, and from
150  g neutrophils incubated for
21 h with or without 1,000 U/ml
G-CSF, in the absence or presence
of 25  M CMK, were electro-
phoresed, blotted, and analyzed for
BLyS protein expression using a
specific anti-BLyS polyclonal Abs.
The top arrow indicates the non-
processed 32-kD BLyS, whereas
the bottom arrow indicates the cleaved 17-kD BLyS. The experiment shown is representative of three experiments. (B) Neutrophils (5   106/ml)
were cultured for 21 h with 1,000 U/ml G-CSF, in the absence or presence of 25  M CMK. Culture supernatants were harvested and examined
for BLyS and IL-1ra content. Values represent means   SEM of duplicate determinations calculated from three independent experiments. 
Figure 4. Neutrophil-derived supernatants promote B cell proliferation
and survival. [3H]Thymidine incorporation by human tonsillar B cells (A)
and flow cytometry analysis on FSC/SSC plots of splenocytes from C57BL/6J mice (B) were assessed after a 4- or 3-d culture, respectively, with 5 ng/ml
rBLyS or conditioned medium prepared from G-CSF–stimulated neutrophils, in the absence or presence of 0.3  g/ml of neutralizing anti-BLyS mAbs.
10 5 dilution SAC was added as a costimulus for the proliferation assay. Cell-free culture medium containing G-CSF was used as a control. Values in A
are expressed as the mean number   SEM of triplicate determinations calculated from three independent experiments. The plots in B are representative
of three separate experiments.T
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medium containing G-CSF only was substantially ineffec-
tive. Similar findings were subsequently obtained in a sur-
vival assay of murine splenocytes evaluated either by mor-
phology (Fig. 4 B) or by annexin V/PI staining (unpublished
data), as reported previously (10). Proliferation and survival
of B cells were BLyS-specific because they were completely
abrogated by the neutralizing anti-BLyS mAbs (but not by
isotype matched control Abs; unpublished data), and were
comparable to that induced by 5 ng/ml BLyS (1, 5).
 
BLyS Production by Neutrophils Isolated from G-CSF–
treated Patients.
 
Finally, we examined the capacity to pro-
duce BLyS by neutrophils purified from patients under-
going administration of rG-CSF. Under these conditions,
G-CSF is known to selectively promote the proliferation and
the differentiation of neutrophil progenitors in vivo and to
activate mature neutrophils (12). We evaluated BLyS serum
levels and BLyS production by leukocytes (measured as
cell-associated protein), either before G-CSF infusion (T-
0), or at day 
 
 
 
12 to 
 
 
 
14 after treatment (T-G-CSF),
when neutrophil count resulted 
 
 
 
1,000/
 
 
 
l (13). Similar to
previous reports (12, 13), preinjection endogenous levels of
G-CSF, measured in serum, were undetectable, whereas
12–14-d posttreatment levels were, on average, 1,170 
 
 
 
248 pg/ml. Fig. 5 A shows that T-0 neutrophils contain
amounts of cell-associated BLyS at levels substantially simi-
lar to those observed in neutrophils freshly purified from
healthy donors (171 
 
 
 
 40 pg/ml, 
 
n
 
 
 
  
 
8). Remarkably, ac-
cumulation of cell-associated BLyS in T-G-CSF neutro-
phils was significantly enhanced, increasing, on average,
three- to fourfold (Fig. 5 A). In contrast, analysis of intra-
cellular BLyS in autologous PBMC, performed before and
after, G-CSF administration, demonstrated that the accu-
mulation of cell-associated BLyS did not significantly
change (resulting 185 
 
 
 
 31 pg/ml at T-0, and 267   27
pg/ml at T-G-CSF, n   4; unpublished data). Importantly,
analysis of serum samples obtained from all these individu-
als revealed that G-CSF administration was associated with
a marked increase in BLyS serum levels, which raised from
values of 3,393   355 pg/ml (at T-0) to 6,494   757 pg/
ml (at T-G-CSF; n   4, P   0.002). Average values of
BLyS serum levels in healthy donors corresponded to
2,945   334 (n   8). Furthermore, in three matched pa-
tients without G-CSF support, serum levels of BLyS as well
as neutrophil-associated BLyS did not change over time
(unpublished data), indicating that the rise of BLyS in
treated patients is a specific effect of G-CSF.
To demonstrate that G-CSF administered to the patients
is directly responsible for the increased levels of BLyS in
the sera, neutrophils from healthy donors were cultured for
21 h in medium containing 20% serum obtained from two
of our patients (before and after G-CSF administration), in
the presence or the absence of neutralizing anti–G-CSF
Abs (Fig. 5 B). The amounts of G-CSF present in these
sera corresponded to 0 pg/ml at T-0 and  1,200 pg/ml at
T-G-CSF. As a control, neutrophils were also cultured
with 100 U/ml G-CSF in the presence or the absence of
neutralizing anti–G-CSF polyclonal Abs. As shown in Fig.
5 B, medium containing T-G-CSF serum stimulated a
higher expression of BLyS in neutrophils than medium
containing T-0 serum. The enhancement of cell-associated
BLyS was blocked (80% inhibition) by neutralizing anti–G-
CSF Abs (Fig. 5 B), whereas negative control Abs was inef-
fective (unpublished data).
In this paper, we demonstrate that human neutrophils
activated by G-CSF and IFN  display the capacity to pro-
duce BLyS. It is worthwhile to remark that, although the
capacity of neutrophils to produce cytokines is low com-
pared with mononuclear cells (6), the amount of BLyS re-
lease by G-CSF–treated neutrophils was similar to that of
IFN -treated monocytes and mono-DC. Because neutro-
phils constitute the most numerous leukocytes in the blood
(normally 50–70%), and are the predominant infiltrating
cells present in acute inflammatory response, they might
Figure 5. BLyS production by neutrophils isolated from G-CSF–treated
patients. (A) Neutrophils were collected from patients either before G-CSF
infusion (T-0) or at day  12 to  14 after treatment (T-G-CSF), lysed, and
examined for cell-associated BLyS by ELISA. The plot shows the mean
values of averaged duplicate determinations obtained from the number
of subjects indicated. (B) Serum samples obtained from two different
patients (both at T-0 and T-G-CSF) were preincubated for 2 h at 37 C
in the presence or absence of 5  g/ml neutralizing anti–G-CSF and
added to neutrophils isolated from normal donors (at a final 20% vol/vol
concentration). As a control, neutrophils were also incubated with
100 U/ml G-CSF (  anti–G-CSF Abs). The mean values   SEM of
BLyS levels associated to neutrophil pellets are shown. The asterisks
represent significant differences between stimulated and resting neutrophils.
*, P   0.05 (n   3).T
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represent a major source of BLyS. What could be the phys-
iological or pathological meaning of the ability of neutro-
phils to produce BLyS? Because neutrophils do not colo-
calize with naive B cells within secondary lymphoid
organs, and do not express membrane-bound BLyS, we
exclude that they might have a direct role in the regulation
of naive B lymphocyte proliferation under physiological
conditions. However, high amounts of BLyS produced by
activated neutrophils in pathological conditions, such as
chronic infection or inflammation, might produce local ef-
fects and/or promote BLyS efflux to local lymphoid tissues
via the lymphatics or the blood. In this way, neutrophil-
derived BLyS might influence B cell maturation in the
spleen and lymph nodes or even promote B cell hyperplasia
and the emergence of autoreactive pathogenic B cells.
The potent G-CSF stimulation of BLyS production in
neutrophils is a finding that, in light of G-CSF’s previously
reported poor capacity to modulate neutrophil-derived cy-
tokines (6), is of great interest and needs to be further inves-
tigated. Elevated concentrations of G-CSF have been found
in the serum and in the synovial fluid of rheumatoid arthritis
patients (14), and in the serum of patients during acute stages
of bacterial infections (12) diseases with pathogenesis associ-
ated with neutrophil activation. In contrast, BLyS serum lev-
els have been shown to be significantly increased in patients
with immune-based diseases such as rheumatoid arthritis
(15), systemic lupus erythematosus (16), and Sjogren’s syn-
drome (17). Understanding whether the increased BLyS lev-
els result from G-CSF–mediated activation of neutrophils
might help to clarify the mechanisms underlying the devel-
opment of autoimmune diseases. Indeed, it has been pro-
posed a potential link between the activation of innate im-
munity occurring during infections and the subsequent
development of autoimmune phenomena (18).
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